Equities analysts expect that Thermo Fisher Scientific Inc. (NYSE:TMO) will report $6.19 billion in sales for the current quarter, Zacks reports. Six analysts have issued estimates for Thermo Fisher Scientific’s earnings, with estimates ranging from $6.18 billion to $6.21 billion. Thermo Fisher Scientific posted sales of $5.92 billion during the same quarter last year, which suggests a positive year over year growth rate of 4.6%. The business is scheduled to issue its next earnings results on Wednesday, October 23rd.

According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $25.42 billion for the current fiscal year, with estimates ranging from $25.39 billion to $25.47 billion. For the next financial year, analysts expect that the firm will report sales of $26.88 billion, with estimates ranging from $26.72 billion to $27.05 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, beating the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company had revenue of $6.32 billion for the quarter, compared to the consensus estimate of $6.31 billion. During the same quarter last year, the company posted $2.75 earnings per share. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year.

A number of research firms recently issued reports on TMO. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price on the stock in a research note on Wednesday, June 12th. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. BTIG Research boosted their target price on shares of Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 30th. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $303.17.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the sale, the chief executive officer now directly owns 342,193 shares in the company, valued at approximately $97,466,832.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the transaction, the director now owns 28,592 shares in the company, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. 0.45% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. Tower Bridge Advisors increased its position in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Tower Bridge Advisors now owns 32,429 shares of the medical research company’s stock valued at $8,876,000 after purchasing an additional 90 shares during the period. Royal London Asset Management Ltd. boosted its stake in Thermo Fisher Scientific by 5.7% during the first quarter. Royal London Asset Management Ltd. now owns 256,760 shares of the medical research company’s stock worth $70,257,000 after buying an additional 13,737 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Thermo Fisher Scientific by 9.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 135,334 shares of the medical research company’s stock valued at $37,044,000 after buying an additional 11,350 shares during the period. Cullen Frost Bankers Inc. bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $64,000. Finally, Renaissance Group LLC bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $27,191,000. Institutional investors and hedge funds own 88.19% of the company’s stock.

Shares of Thermo Fisher Scientific stock traded up $5.44 on Friday, reaching $294.94. The stock had a trading volume of 1,123,378 shares, compared to its average volume of 1,583,402. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The business’s 50-day moving average price is $280.90 and its two-hundred day moving average price is $276.38. The stock has a market cap of $116.95 billion, a P/E ratio of 26.52, a price-to-earnings-growth ratio of 1.91 and a beta of 1.12. Thermo Fisher Scientific has a fifty-two week low of $208.34 and a fifty-two week high of $305.45.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.